Backgrounds: Platinum-based doublets are recommended as first-line treatment of stage IV non-small-cell lung cancer (NSCLC). Oxaliplatin is more potent than cisplatin, requiring fewer DNA adducts to provide equivalent cytotoxicity. The objective of this study is to evaluate the efficacy and safety of oxaliplatin combined with docetaxel as a first line treatment of stage IV NSCLC. Methods: This is prospective, single-center, phase II trial. Patients with chemotherapy-naive NSCLC received docetaxel 60 mg/m2 (day 1) and oxaliplatin 70 mg/m2 (day 2) every 3 weeks for up to 6 cycles. The primary endpoint was objective response rate (ORR) and the secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety. Treatment response was evaluated according to version 1.1 of Response Evaluation Criteria in Solid Tumors. Results: For this preliminary analysis, 33 patients were enrolled and response evaluation was possible in 31. In response evaluable patients, there were no complete response, 10 partial response, 17 stable disease. ORR was 30.3% and disease control rate was 81.8%. Median PFS was 127 days (95% confidence interval, 59-195) and median OS was 394 days (95% confidence interval, 264-524). Grade 3-4 toxicities occurred in 45% of patients, and the most common hematologic toxicity was neutropenia. There were two cases of hyperglycemia and sepsis. Conclusions: This study suggests that the combination of oxaliplatin and docetaxel is effective in patients with NSCLC, with reasonable toxicities.